Benin vs Philippines: Average cost of multi drug-resistant tuberculosis treatment
Benin
426 constant 2022 US$
in 2024
Philippines
310 constant 2022 US$
in 2024
Benin rank
86th
Philippines rank
89th
Average cost of multi drug-resistant tuberculosis treatment over time
- Benin
- Philippines
How they compare
Benin currently reports 426 constant 2022 US$ against 310 constant 2022 US$ in Philippines, a difference of 116 constant 2022 US$.
That makes Benin's figure about 1.4 times Philippines's.
The two have swapped places 3 times across 8 shared years of data; in 2017 it was Philippines ahead.
Benin ranks 86th and Philippines ranks 89th of 92 countries.
Philippines has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Benin | Philippines | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 1,013 constant 2022 US$ | 4,921 constant 2022 US$ | 3,908 constant 2022 US$ | Philippines |
| 2020s | 865.8 constant 2022 US$ | 1.36 million constant 2022 US$ | 1.35 million constant 2022 US$ | Philippines |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, Benin or Philippines?
- Benin, at 426 constant 2022 US$ against 310 constant 2022 US$ in Philippines as of 2024.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between Benin and Philippines?
- 116 constant 2022 US$, with Benin ahead.
- How many years of comparable data are there for Benin and Philippines?
- 8 years are reported by both, from 2017 to 2024.
- How do Benin and Philippines rank globally for average cost of multi drug-resistant tuberculosis treatment?
- Benin ranks 86th and Philippines ranks 89th of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.